A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

Faculty and Topics When Hodgkin and Non-Hodgkin Lymphomas/ Michael Birrer, MD, PhD Saturday, October 28, 2017 Chronic Lymphocytic Leukemia University of Alabama at Birmingham Birmingham, Alabama 8:00 AM to 4:00 PM Jeremy Abramson, MD Massachusetts General Hospital Acute Leukemias Cancer Center Where Boston, Massachusetts Harry P Erba, MD, PhD University of Alabama at Birmingham JW Marriott Orlando Ann S LaCasce, MD, MMSc Birmingham, Alabama Grande Lakes Dana-Farber Cancer Institute Boston, Massachusetts Hagop M Kantarjian, MD 4040 Central Florida Parkway The University of Texas Sonali M Smith, MD Orlando, FL 32837 MD Anderson Cancer Center The University of Chicago Houston, Texas Chicago, Illinois Mediterranean Ballroom 1-4 Lung Cancer (Lobby Level) Breast Cancer Gregory J Riely, MD, PhD Breakfast and lunch provided Joyce O’Shaughnessy, MD Memorial Sloan Kettering Cancer Center Baylor Charles A Sammons Cancer Center New York, New York Dallas, Texas Moderator David R Spigel, MD Hope S Rugo, MD Neil Love, MD Sarah Cannon Research Institute University of California, San Francisco Nashville, Tennessee Research To Practice San Francisco, California Heather Wakelee, MD Miami, Florida Genitourinary Cancers Stanford Cancer Institute William K Oh, MD Stanford, California This activity is being hosted Icahn School of Medicine at Mount Sinai Gastrointestinal Cancers in association with New York, New York Jordan D Berlin, MD Daniel P Petrylak, MD Vanderbilt University Medical Center Yale Cancer Center Nashville, Tennessee New Haven, Connecticut Axel Grothey, MD Ovarian Cancer Mayo Clinic Deborah K Armstrong, MD Rochester, Minnesota Johns Hopkins University Baltimore, Maryland

To register or to learn more please visit: www.ResearchToPractice.com/Meetings/YIR2017/FL This event is free of charge.

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology and Tesaro Inc. CME/CNE Information

Target Audience CNE Credit Designation Statements These live activities have been designed This educational activity for 6.6 contact to meet the educational needs of medical hours is provided by Research To Practice. oncologists, hematologists, hematology- This activity is awarded 6.6 ANCC pharmaco- oncology fellows, nurse practitioners, therapeutic contact hours. clinical nurse specialists and other allied cancer professionals. ONCC/ILNA Certification Information Learning Objectives and Goals This program will be submitted for ONCC/ ILNA certification. At the conclusion of each activity, partici- pants should be able to: CME Credit Form • Effectively apply the results of practice- A credit form will be given to each partici- changing clinical research to the care of pant at the conclusion of the activity. patients with breast, lung, gastrointes- CNE Credit Form tinal, genitourinary, ovarian and select To obtain a certificate of completion and hematologic cancers. receive credit for this event, nurses must • Appraise the clinical relevance of recent sign in at the registration desk upon arrival, pivotal cancer research results published attend the entire activity and return a in peer-reviewed journals and/or completed Educational Assessment and presented at major oncology conferences. Credit Form upon exiting the activity. • Recall ongoing trials in breast, lung, Disclosure Policy gastrointestinal, genitourinary, ovarian Research To Practice (RTP) is committed to and select hematologic cancers, and providing its participants with high-quality, refer appropriate patients for study unbiased and state-of-the-art education. participation. We assess conflicts of interest with faculty, • Use an understanding of tumor planners and managers of CME/CNE activi- biomarkers and single and multigene ties. Conflicts of interest are identified and signatures to individualize the care of resolved through a conflict of interest resolu- patients with cancer. tion process. In addition, all activity content • Educate patients with diverse hematologic is reviewed by both a member of the RTP cancers and solid tumors about the scientific staff and an external, independent benefits and risks of new therapeutic reviewer for fair balance, scientific objectivity agents and strategies. of studies referenced and patient care recom- • Refine or validate existing cancer-specific mendations. Financial disclosures will be treatment algorithms based on exposure provided in meeting course materials. to new data sets and the perspectives of Unlabeled/Unapproved Uses Notice tumor-specific clinical investigators. There is no implied or real endorsement of • Evaluate the mechanisms of action, toler- any product by Research To Practice, the ability and efficacy of promising investiga- Accreditation Council for Continuing Medical tional agents, and consider their potential Education or the American Nurses Creden- implications for clinical practice. tialing Center.

CME Accreditation Statement Educational Support Research To Practice is accredited by the These activities are supported by educational Accreditation Council for Continuing Medical grants from AbbVie Inc, Agios Pharmaceuti- Education to provide continuing medical cals Inc, Amgen Inc, AstraZeneca Pharma- education for physicians. ceuticals LP, Bayer HealthCare Pharmaceuti- CNE Accreditation Statement cals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol- Research To Practice is accredited as a Myers Squibb Company, Celgene Corpora- provider of continuing nursing education by tion, Clovis Oncology, Eisai Inc, Exelixis Inc, the American Nurses Credentialing Center’s Genentech BioOncology, Genomic Health Inc, Commission on Accreditation. Gilead Sciences Inc, ImmunoGen Inc, Ipsen CME Credit Designation Statement Biopharmaceuticals Inc, Lexicon Pharmaceu- Research To Practice designates this live ticals Inc, Lilly, Novartis, Pfizer Inc, Pharma- activity for a maximum of 6.75 AMA PRA cyclics LLC, an AbbVie Company, Sanofi Category 1 Credits™. Physicians should claim Genzyme, Seattle Genetics, Taiho Oncology only the credit commensurate with the Inc, Takeda Oncology and Tesaro Inc. extent of their participation in the activity. Agenda Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology. All events will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided). Please consult www.ResearchToPractice.com/Meetings/YIR2017 for a detailed sched- ule including module order and times for each program.

MODULE 1: Gastrointestinal Cancers • Ongoing investigation of other novel agents and strategies in GI cancers (eg, napabu- • Patient and disease characteristics guiding casin, PEGPH20) therapy for patients with metastatic colorectal cancer (mCRC), including primary tumor location and presence of MODULE 2: Hodgkin and Non-Hodgkin potentially targetable genetic abnormali- Lymphomas/Chronic Lymphocytic ties (eg, BRAF, HER2) Leukemia • FDA approval of and for patients with microsatellite • Selection of up-front treatment for chronic instability-high or mismatch repair- lymphocytic leukemia (CLL) in younger and deficient tumors; integration into current older patients with normal- and high-risk mCRC treatment algorithms cytogenetics • Rational incorporation of regorafenib and • Emerging research evidence with and TAS-102 into the treatment algorithm for nonprotocol role, if any, of maintenance mCRC and early activity and safety data in therapy in CLL treatment-refractory gastric cancer • Practical integration of venetoclax into • Integration of into clinical clinical algorithms; emerging data with algorithms for metastatic HER2-negative use beyond del(17p) disease and HER2-positive gastric/gastroesopha- • Novel strategies under investigation geal junction (GEJ) cancer in CLL (eg, acalabrutinib, ublituximab, • Ongoing evaluation and current off- anti-PD-1/PD-L1 antibodies) protocol role, if any, of FOLFIRINOX or • FDA approval of subcutaneous nanoparticle albumin-bound (nab) pacli- and potential clinical utility taxel/gemcitabine for patients with • Efficacy and safety of -based pancreatic adenocarcinoma in the induction and maintenance therapy for neoadjuvant and adjuvant settings patients with previously untreated follic- • Optimal integration of nanoliposomal ular lymphoma (FL) irinotecan (nal-IRI) into clinical practice • Available data with and ongoing evaluation • Recent FDA approval of pembrolizumab of the “R squared” regimen in FL for PD-L1-positive recurrent or advanced • Recent FDA accelerated approval of gastric/GEJ adenocarcinoma after 2 or copanlisib for relapsed FL and ongoing more lines of and, if appro- investigation of novel agents (eg, ibrutinib, priate, HER2-targeted therapy; ongoing venetoclax, ) trials of anti-PD-1/PD-L1 antibodies alone • Available and emerging research informa- or in combination with other systemic or tion with novel agents as a component of immunotherapeutic approaches induction and/or post-transplant mainte- • Implications for clinical practice of the nance therapy in mantle cell lymphoma recent FDA approvals of regorafenib and and treatment options for patients with nivolumab for patients with hepatocellular relapsed/refractory (R/R) disease carcinoma (HCC) previously treated with • Preliminary outcomes with brentuximab sorafenib vedotin (BV) as a component of first-line • Emerging data comparing lenvatinib therapy for patients with Hodgkin to sorafenib in patients with advanced, lymphoma (HL); practical considerations unresectable HCC with the use of BV as a bridge to or as • Clinical utility and optimal employment of consolidation after transplant long-acting somatostatin analogues for • FDA approvals of nivolumab and pembro- neuroendocrine tumors (NETs) lizumab for patients with R/R HL; ongoing • Current clinical role of everolimus for evaluation of immune checkpoint inhibi- patients with locally advanced or meta- tors alone or in combination with other static, nonfunctional NET of lung or immunotherapies or targeted agents in HL gastrointestinal (GI) origin • Available and emerging research infor- • Recent FDA approval of telotristat ethyl for mation with lenalidomide and ibrutinib in patients with carcinoid syndrome and find- newly diagnosed and R/R diffuse large ings from recent Phase III trials B-cell lymphoma (DLBCL) • Emerging research evidence with and recombination deficiency) that may predict potential clinical role of CAR T-cell therapy benefit from PARP inhibition for patients with DLBCL and other aggres- • Optimal integration of niraparib, olaparib sive lymphomas and rucaparib into current ovarian cancer • Patient- and/or disease-specific factors (OC) treatment algorithms; ongoing evalu- guiding the sequence and selection of ation of investigational PARP inhibitors belinostat, pralatrexate and romidepsin in • Clinical role of niraparib and olaparib T-cell lymphoma as maintenance therapy; Phase III study • Clinical implications and prognostic role of results with maintenance rucaparib minimal residual disease detection in CLL • Recognition and management of PARP and various lymphoma subtypes inhibitor-related side effects (anemia, GI toxicity, pneumonitis, et cetera) MODULE 3: Breast Cancer • Patient selection for neoadjuvant systemic therapy; available data defining the optimal • Available and emerging data guiding neoadjuvant regimen the use of genomic assays to optimize deci- • Risks and benefits of intraperitoneal sion-making regarding adjuvant chemo- chemotherapy; indications for its use in therapy and extended endocrine therapy clinical practice • Factors affecting the selection and • Optimal integration of in sequence of systemic therapy for ER- combination with chemotherapy followed positive metastatic breast cancer (mBC) by maintenance bevacizumab into the • FDA approval of ribociclib and integration treatment algorithm for patients with plat- of CDK4/6 inhibitors into clinical algo- inum-sensitive recurrent OC rithms for patients with ER-positive mBC • Mechanism of action of, available efficacy • Recent FDA approval of and Phase III effi- data with and ongoing trials evaluating the cacy and safety findings with abemaciclib role of mirvetuximab soravtansine in ER-positive mBC; potential clinical role • Available safety and efficacy data with and • Results and clinical implications of the ongoing trials evaluating anti-PD-1/PD-L1 Phase III APHINITY trial comparing antibodies in patients with OC adjuvant chemotherapy/ to chemotherapy/trastuzumab/ MODULE 5: Genitourinary Cancers for HER2-positive early BC • Recent FDA approval of neratinib as • Research database supporting the recent extended adjuvant therapy: Patient selec- FDA approvals of , avelumab, tion and use in clinical practice durvalumab, nivolumab and pembroli- • Ongoing and planned clinical trials incor- zumab in urothelial bladder cancer (UBC); porating novel HER2-directed therapies patient selection for and use of these in the neoadjuvant and adjuvant settings agents in clinical practice • Published data examining the use of • Active and planned clinical trials of combined endocrine and anti-HER2 immune checkpoint inhibitors alone or in blockade for triple-positive mBC combination for early and advanced UBC • Diagnostic and therapeutic implications of • Results of clinical trials evaluating the OlympiAD trial documenting a progres- (neo)adjuvant anti-VEGF therapy for sion-free survival advantage with olaparib unfavorable/high-risk localized or locally versus chemotherapy for patients with advanced renal cell carcinoma (RCC) germline BRCA mutation-positive, HER2- • Optimal selection of VEGF-directed negative mBC therapy for newly diagnosed metastatic • Available data with and ongoing evalu- RCC (mRCC) ation of anti-PD-1/PD-L1 antibodies as • Current clinical role of nivolumab in monotherapy or in combination with other advanced RCC; ongoing trials evaluating systemic agents immune checkpoint inhibitors in RCC • Other novel agents and approaches under • Clinical experience with cabozantinib investigation for HER2-positive and triple- and current role in the management of negative BC advanced RCC; available data with first- line therapy MODULE 4: Ovarian Cancer • Integration of lenvatinib/everolimus into the care of patients with mRCC • Similarities and differences between avail- • Investigational approaches with enzalu- able genetic testing platforms; role of tamide, abiraterone and sipuleucel-T in extended panel testing/next-generation patients with nonmetastatic castration- sequencing resistant prostate cancer (CRPC) • Identification of “BRCA-like” and other genomic signatures (eg, homologous Agenda (continued)

• Available Phase III data with and potential • Novel agents under evaluation in small cell clinical role of adding abiraterone/pred- lung cancer and malignant pleural meso- nisone to standard hormonal therapy for thelioma patients with hormone-sensitive meta- static prostate cancer MODULE 7: Acute Leukemias • Clinical and biologic factors affecting the sequence and selection of secondary • Evidence-based induction regimens and hormonal therapy, immunotherapy and postinduction consolidation and/or mainte- cytotoxic therapy for patients with meta- nance therapy for younger/fit patients with static CRPC (mCRPC) acute myeloid leukemia (AML) • Current indications for radium-223 chlo- • Optimal integration of CPX-351 into the ride in clinical practice and rational combi- treatment of newly diagnosed therapy- nation strategies (eg, other bone-targeted related AML or AML with myelodysplasia- or secondary hormonal therapy) related changes • Incidence of somatic or germline mutations • Indications for the use of hypomethylating in BRCA1, BRCA2 or ATM in patients with agents as induction and/or maintenance mCRPC; ongoing evaluation of PARP inhibi- therapy in elderly patients or those with tion as a therapeutic strategy poor-risk AML • FDA approval of midostaurin for patients MODULE 6: Lung Cancer with newly diagnosed AML and a FLT3 mutation; patient selection and practical • First-line treatment options for patients aspects related to its administration with EGFR mutation-positive disease; • Mechanisms of action and available potential implications of the Phase III research data with the recently FDA- FLAURA trial results approved IDH1/2 inhibitor enasidenib; • Available efficacy and safety data with ongoing evaluation of novel IDH1/2 osimertinib; effectiveness in patients with (eg, ivosidenib [AG-120]) and FLT3 (eg, CNS metastases gilteritinib, quizartinib) inhibitors in AML • Selection of first-, second- and later-line • Recent FDA approval and current clin­ical therapy for patients with ALK- or ROS1- role of for positive disease; implications of recent CD33-positive AML data sets and drug approvals • Other novel agents under evaluation in • Recent FDA approval of dabrafenib/ AML (eg, venetoclax, pracinostat, GMI-1271) trametinib for patients with BRAF V600E • Selection and sequencing of therapy for tumor mutations patients with Philadelphia chromosome- • Potential treatment options for patients positive and negative acute lymphoblastic with other oncogenic mutations (eg, HER2, leukemia (ALL) MET exon 14, RET, NTRK gene fusions) • FDA approval of CAR T-cell therapy for • Design, efficacy endpoints and available pediatric and young adult patients with data from the PACIFIC trial evaluating the ALL that is refractory or in second or later use of durvalumab as sequential therapy relapse; ongoing clinical investigation for for patients with locally advanced disease older adult patients after completion of definitive chemoradia- • Clinical experience with different prepara- tion therapy tions of asparaginase in young adult and • Available data with and patient selection adult patients with ALL for pembrolizumab with and without • Patient selection for in ALL chemotherapy in individuals with newly clinical practice diagnosed metastatic non-small cell lung • Available research data supporting the cancer (NSCLC) recent FDA approval of inotuzumab • Ongoing trials of anti-PD-1/PD-L1 ozogamicin in R/R B-cell precursor ALL antibodies in combination with other • Diagnostic considerations for acute immunotherapeutic, chemotherapeutic promyelocytic leukemia; investigational or targeted approaches approaches for low/intermediate-risk • Selection of first-line therapy for patients disease; choice of induction regimen for with PD-L1-negative squamous NSCLC patients with high-risk disease • Rational integration of ramucirumab into the management of nonsquamous and squamous NSCLC